Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

Patients with high risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) are commonly older with multiple co-morbidities, rendering them unsuitable for intensive induction chemotherapy or transplantation. We report preliminary cellular immune profiling of four cases receiving seq...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Prachi, Klotz, Jeffrey, Dunavin, Neil, Lu, Kit, Koklanaris, Eleftheria, Draper, Debbie, Superata, Jeanine, Chinian, Fariba, Yu, Quan, Keyvanfar, Keyvan, Wong, Susan, Muranski, Pawel, Barrett, A. John, Ito, Sawa, Battiwalla, Minoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402630/
https://www.ncbi.nlm.nih.gov/pubmed/28462085
http://dx.doi.org/10.1016/j.lrr.2017.04.003
_version_ 1783231263720603648
author Jain, Prachi
Klotz, Jeffrey
Dunavin, Neil
Lu, Kit
Koklanaris, Eleftheria
Draper, Debbie
Superata, Jeanine
Chinian, Fariba
Yu, Quan
Keyvanfar, Keyvan
Wong, Susan
Muranski, Pawel
Barrett, A. John
Ito, Sawa
Battiwalla, Minoo
author_facet Jain, Prachi
Klotz, Jeffrey
Dunavin, Neil
Lu, Kit
Koklanaris, Eleftheria
Draper, Debbie
Superata, Jeanine
Chinian, Fariba
Yu, Quan
Keyvanfar, Keyvan
Wong, Susan
Muranski, Pawel
Barrett, A. John
Ito, Sawa
Battiwalla, Minoo
author_sort Jain, Prachi
collection PubMed
description Patients with high risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) are commonly older with multiple co-morbidities, rendering them unsuitable for intensive induction chemotherapy or transplantation. We report preliminary cellular immune profiling of four cases receiving sequential clofarabine and lenalidomide for high risk MDS and AML in a phase I study. Our results highlight the potential of immune profiling for monitoring immune-modifying agents in high risk MDS and AML.
format Online
Article
Text
id pubmed-5402630
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-54026302017-05-01 Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia Jain, Prachi Klotz, Jeffrey Dunavin, Neil Lu, Kit Koklanaris, Eleftheria Draper, Debbie Superata, Jeanine Chinian, Fariba Yu, Quan Keyvanfar, Keyvan Wong, Susan Muranski, Pawel Barrett, A. John Ito, Sawa Battiwalla, Minoo Leuk Res Rep Article Patients with high risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) are commonly older with multiple co-morbidities, rendering them unsuitable for intensive induction chemotherapy or transplantation. We report preliminary cellular immune profiling of four cases receiving sequential clofarabine and lenalidomide for high risk MDS and AML in a phase I study. Our results highlight the potential of immune profiling for monitoring immune-modifying agents in high risk MDS and AML. Elsevier 2017-04-13 /pmc/articles/PMC5402630/ /pubmed/28462085 http://dx.doi.org/10.1016/j.lrr.2017.04.003 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Jain, Prachi
Klotz, Jeffrey
Dunavin, Neil
Lu, Kit
Koklanaris, Eleftheria
Draper, Debbie
Superata, Jeanine
Chinian, Fariba
Yu, Quan
Keyvanfar, Keyvan
Wong, Susan
Muranski, Pawel
Barrett, A. John
Ito, Sawa
Battiwalla, Minoo
Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia
title Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia
title_full Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia
title_fullStr Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia
title_full_unstemmed Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia
title_short Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia
title_sort cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402630/
https://www.ncbi.nlm.nih.gov/pubmed/28462085
http://dx.doi.org/10.1016/j.lrr.2017.04.003
work_keys_str_mv AT jainprachi cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT klotzjeffrey cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT dunavinneil cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT lukit cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT koklanariseleftheria cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT draperdebbie cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT superatajeanine cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT chinianfariba cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT yuquan cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT keyvanfarkeyvan cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT wongsusan cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT muranskipawel cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT barrettajohn cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT itosawa cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia
AT battiwallaminoo cellularimmuneprofilingaftersequentialclofarabineandlenalidomideforhighriskmyelodysplasticsyndromesandacutemyeloidleukemia

Ejemplares similares